Topoisomerase II Inhibitors
"Topoisomerase II Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II.
| Descriptor ID |
D059005
|
| MeSH Number(s) |
D27.505.519.389.892.750 D27.505.954.248.794.750
|
| Concept/Terms |
Topoisomerase II Inhibitors- Topoisomerase II Inhibitors
- Inhibitors, Topoisomerase II
- DNA Type 2 Topoisomerase Inhibitors
- Topoisomerase 2 Inhibitors
- Inhibitors, Topoisomerase 2
- DNA Topoisomerase II Inhibitors
|
Below are MeSH descriptors whose meaning is more general than "Topoisomerase II Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Topoisomerase II Inhibitors".
This graph shows the total number of publications written about "Topoisomerase II Inhibitors" by people in this website by year, and whether "Topoisomerase II Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2017 | 0 | 2 | 2 |
| 2018 | 2 | 1 | 3 |
| 2019 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Topoisomerase II Inhibitors" by people in Profiles.
-
SARS-CoV-2 entry inhibitors by dual targeting TMPRSS2 and ACE2: An in silico drug repurposing study. Eur J Pharmacol. 2021 Apr 05; 896:173922.
-
Phytochemicals from Selective Plants Have Promising Potential against SARS-CoV-2: Investigation and Corroboration through Molecular Docking, MD Simulations, and Quantum Computations. Biomed Res Int. 2020; 2020:6237160.
-
The AI-discovered aetiology of COVID-19 and rationale of the irinotecan+ etoposide combination therapy for critically ill COVID-19 patients. Med Hypotheses. 2020 Nov; 144:110180.
-
Etoposide treatment adjunctive to immunosuppressants for critically ill COVID-19 patients. J Infect. 2020 09; 81(3):452-482.
-
Secondary hemophagocytic lymphohistiocytosis, HScore and COVID-19. Int J Hematol. 2020 Jul; 112(1):125-126.
-
Reply to the letter by Gaetano Loscocco, Secondary hemophagocytic lymphohistiocytosis, HScore and COVID-19. Int J Hematol. 2020 Jul; 112(1):127.
-
Possible role of low-dose etoposide therapy for hemophagocytic lymphohistiocytosis by COVID-19. Int J Hematol. 2020 Jul; 112(1):122-124.
-
Large-scale chemical-genetics yields new M. tuberculosis inhibitor classes. Nature. 2019 07; 571(7763):72-78.
-
Discovery of Novel Topoisomerase II Inhibitors by Medicinal Chemistry Approaches. J Med Chem. 2018 10 25; 61(20):8947-8980.
-
Pregnancy planning and outcomes in patients with multiple sclerosis after mitoxantrone therapy: a monocentre assessment. Eur J Neurol. 2018 08; 25(8):1063-1068.